Skip to main content
. 2020 Mar 2;11:1148. doi: 10.1038/s41467-020-14959-w

Table 4.

Association results and heterogeneity estimates for metabolites in relation to A-T-N biomarkers in APOE ε4 carriers stratified by sex.

Biomarker/metabolite Pooled effect Pooled p value Sex diff. p value Sex diff. I² ε4 diff. p value ε4 diff. I² ε4+ (m) effect ε4+ (m) p value ε4+ (f) effect ε4+ (f) p value
Pathological CSF 1–42
PC ae C44:6 0.283 2.58E-04 9.15E-01 0.000 6.83E-03 63.03 0.463 1.68E-02 0.922 1.90E-04
PC ae C44:5 0.26 5.23E-04 6.01E-01 0.000 4.56E-03 64.749 0.521 6.17E-03 0.761 8.29E-04
PC ae C42:4 0.242 1.98E-03 7.58E-01 0.000 9.61E-03 61.382 0.42 3.15E-02 0.761 8.65E-04
CSF p-tau
C10 0.084 4.58E-03 2.76E-02 54.613 6.16E-01 0 -0.064 3.24E-01 0.264 1.21E-04
FDG-PET
Proline −0.023 4.51E-01 4.50E-03 64.801 2.01E-02 56.977 0.046 4.76E-01 −0.272 8.22E-05

Significant metabolite effects in the combined stratification (sex by APOE ε4 status) on A-T-N biomarkers are driven by or limited to APOE ε4+ females. Given are regression results for the full sample, APOE ε4+ males, APOE ε4+ females, as well as heterogeneity estimates by sex and APOE ε4 status. The only metabolite showing effect heterogeneity for both stratification variables was proline in its association with FDG-PET values. Full association results for all strata are provided in Supplementary Data 2. Sex diff. results from the sex-stratified heterogeneity analysis, ε4 diff. results from the APOE ε4 status-stratified heterogeneity analysis,ε4+ (m)/ε4+ (f) results for APOE ε4+ males and females, respectively.